About paxmedica inc - PXMD
PaxMedica, Inc. is a clinical stage biopharmaceutical company. It engages in the business of developing drug candidates for the treatment of autism spectrum disorder, Fragile X syndrome tremor-ataxia, and Human African Trypanosomiasis. The company was founded by Michael L. Derby on April 5, 2018 and is headquartered in Tarrytown, NY.
PXMD At a Glance
PaxMedica, Inc.
303 South Broadway
Tarrytown, New York 10591
| Phone | 1-914-987-2876 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -18,289,725.00 | |
| Sector | Health Technology | Employees | 7 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
PXMD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.655 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.214 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
PXMD Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,612,817.857 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PXMD Liquidity
| Current Ratio | 3.164 |
| Quick Ratio | 3.164 |
| Cash Ratio | 2.624 |
PXMD Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -463.928 |
| Return on Equity | -1,046.96 |
| Return on Total Capital | -540.305 |
| Return on Invested Capital | -1,046.96 |
PXMD Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |